Ocugen Terminates Material Definitive Agreement
Ticker: OCGN · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $0.001, $25.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Ocugen terminated a big deal, filing 8-K on 9/18.
AI Summary
Ocugen, Inc. announced on September 16, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on September 18, 2025, detailing the event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction and financial obligations.
Risk Assessment
Risk Level: medium — Termination of a material agreement can introduce uncertainty and potential financial or operational risks.
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- September 16, 2025 (date) — Date of Earliest Event Reported
- September 18, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific material definitive agreement was terminated by Ocugen, Inc.?
The filing does not specify the exact name or details of the material definitive agreement that was terminated.
When did the termination of the material definitive agreement become effective?
The earliest event reported, which is the termination, occurred on September 16, 2025.
What is Ocugen, Inc.'s principal executive office address?
Ocugen, Inc.'s principal executive office is located at 11 Great Valley Parkway, Malvern, Pennsylvania 19355.
What is the Commission File Number for Ocugen, Inc.?
Ocugen, Inc.'s Commission File Number is 001-36751.
What is the SIC code for Ocugen, Inc.?
Ocugen, Inc.'s Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 723 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2025-09-18 11:00:37
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
- $0.001 — rger, shares of common stock, par value $0.001 per share, of Carisma ("Common Stock")
- $25.0 million — regate gross proceeds at least equal to $25.0 million (the "Concurrent Investment"). On Septe
Filing Documents
- tm2526448d1_8k.htm (8-K) — 24KB
- 0001104659-25-091097.txt ( ) — 184KB
- ocgn-20250916.xsd (EX-101.SCH) — 3KB
- ocgn-20250916_lab.xml (EX-101.LAB) — 33KB
- ocgn-20250916_pre.xml (EX-101.PRE) — 22KB
- tm2526448d1_8k_htm.xml (XML) — 3KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, on June 22, 2025, Ocugen, Inc. ("Ocugen" or the "Company") and OrthoCellix, Inc., a Delaware corporation and wholly-owned subsidiary of the Company to which the Company has contributed the assets related to the Company's Neocart product candidate ("OrthoCellix"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Ocugen, OrthoCellix, Carisma Therapeutics Inc., a Delaware corporation ("Carisma") and Azalea Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Carisma ("Merger Sub"), pursuant to which, among other matters, Merger Sub would merge with and into OrthoCellix (the "Merger"), with OrthoCellix continuing as a wholly owned subsidiary of Carisma and the surviving company of the Merger. Pursuant to the Merger Agreement, Carisma and OrthoCellix agreed to use commercially reasonable efforts to enter into subscription agreements with one or more investors designated by OrthoCellix (the "Investors"), pursuant to which such anticipated Investors would agree to purchase, at or immediately following the closing of the Merger, shares of common stock, par value $0.001 per share, of Carisma ("Common Stock") for aggregate gross proceeds at least equal to $25.0 million (the "Concurrent Investment"). On September 16, 2025, Carisma delivered a termination notice to the Company, providing for the termination of the Merger Agreement pursuant to Section 9.1(k) of the Merger Agreement as a result of the Company having obtained less than $25.0 million in commitments for the Concurrent Investment sufficiently in advance of Carisma's pending Nasdaq compliance deadline of October 7, 2025. Ocugen believes poor market conditions and the short timeline for Nasdaq compliance contributed to the difficulty in securing the Concurrent Investment. The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its ent